2025
Impact of Preoperative LDL Level on Lower Extremity Revascularization Outcomes
Carter W, Alappan U, Chetty A, Wells N, Alameddine D, Slade M, Possick S, Ochoa Chaar C. Impact of Preoperative LDL Level on Lower Extremity Revascularization Outcomes. Annals Of Vascular Surgery 2025, 122: 239-247. PMID: 40651525, DOI: 10.1016/j.avsg.2025.07.016.Peer-Reviewed Original ResearchLower extremity revascularizationPeripheral arterial diseaseRetrospective chart reviewProportion of patientsRetrospective chart review of patientsChart review of patientsLDL testingReview of patientsCox regression analysisAdverse cardiovascular eventsChronic limb-threatening ischemiaHybrid lower extremity revascularizationBurden of comorbiditiesAssociated with outcomeLimb-threatening ischemiaOld white maleBaseline LDLTertiary centerStatin useLipid testingCardiovascular eventsFollow-upLDL levelsLower LDLRevascularization outcomes
2021
Genetic determinants of LDL cholesterol and risk of intracerebral haemorrhage
Szejko N, Kirsch E, Falcone GJ. Genetic determinants of LDL cholesterol and risk of intracerebral haemorrhage. Current Opinion In Lipidology 2021, 32: 244-248. PMID: 34010223, PMCID: PMC10273781, DOI: 10.1097/mol.0000000000000761.Peer-Reviewed Original ResearchConceptsRisk of ICHIntracerebral hemorrhageLDL levelsLDL cholesterolInverse associationClinical trialsLipid levelsObservational studyCerebral small vessel diseaseWhite matter hyperintensity volumeLDL cholesterol levelsLow LDL levelsNontraumatic intracerebral hemorrhageSmall vessel diseaseElevated LDL levelsElevated lipid levelsVessel diseaseCholesterol levelsHigh burdenHyperintensity volumeHigh riskRole of lipidsHemorrhageStatinsRisk
2020
Genetically Elevated LDL Associates with Lower Risk of Intracerebral Hemorrhage
Falcone GJ, Kirsch E, Acosta JN, Noche RB, Leasure A, Marini S, Chung J, Selim M, Meschia JF, Brown DL, Worrall BB, Tirschwell DL, Jagiella JM, Schmidt H, Jimenez‐Conde J, Fernandez‐Cadenas I, Lindgren A, Slowik A, Gill D, Holmes M, Phuah C, Petersen NH, Matouk CN, Gunel M, Sansing L, Bennett D, Chen Z, Sun LL, Clarke R, Walters RG, Gill TM, Biffi A, Kathiresan S, Langefeld CD, Woo D, Rosand J, Sheth KN, Anderson CD, Consortium F. Genetically Elevated LDL Associates with Lower Risk of Intracerebral Hemorrhage. Annals Of Neurology 2020, 88: 56-66. PMID: 32277781, PMCID: PMC7523882, DOI: 10.1002/ana.25740.Peer-Reviewed Original ResearchConceptsIntracerebral hemorrhagePolygenic risk scoresLDL cholesterolLower riskTotal cholesterolICH riskLow-density lipoprotein cholesterol levelsRisk of ICHLipoprotein cholesterol levelsPotential causal roleMendelian randomization analysisAnn NeurolLDL levelsCholesterol levelsICH casesObservational studySD increaseSignificant single nucleotide polymorphismsRisk scoreSignificant associationCholesterolMR analysisInverse correlationRandomization analysisSingle nucleotide polymorphisms
2016
Age‐associated vascular inflammation promotes monocytosis during atherogenesis
Du W, Wong C, Song Y, Shen H, Mori D, Rotllan N, Price N, Dobrian AD, Meng H, Kleinstein SH, Fernandez‐Hernando C, Goldstein DR. Age‐associated vascular inflammation promotes monocytosis during atherogenesis. Aging Cell 2016, 15: 766-777. PMID: 27135421, PMCID: PMC4933655, DOI: 10.1111/acel.12488.Peer-Reviewed Original ResearchMeSH KeywordsAgingAnimalsAortaAtherosclerosisBlood VesselsCell CountChemotaxisCulture Media, ConditionedDiet, High-FatDown-RegulationHematopoiesisHemodynamicsInflammationInflammation MediatorsInsulin ResistanceInterleukin-6LeukocytosisMacrophagesMaleMiceMice, Inbred C57BLMonocytesOligonucleotide Array Sequence AnalysisReceptors, LDLStromal CellsUp-RegulationConceptsHigh-fat dietVascular inflammationMacrophage accumulationAtherosclerotic aortaBone marrow transplant experimentsStromal factorsElevated blood pressureVascular smooth muscle cellsLow-fat dietSmooth muscle cellsBlood pressurePeripheral monocytosisProinflammatory stateInflammatory stateLDL levelsIL-6Insulin resistancePeripheral bloodEnhanced atherogenesisInflammatory responseMetabolic dysfunctionYoung aortasMurine modelProduction of osteopontinCCL-2
2014
The Combined Hyperlipidemia Caused by Impaired Wnt-LRP6 Signaling Is Reversed by Wnt3a Rescue
Go GW, Srivastava R, Hernandez-Ono A, Gang G, Smith SB, Booth CJ, Ginsberg HN, Mani A. The Combined Hyperlipidemia Caused by Impaired Wnt-LRP6 Signaling Is Reversed by Wnt3a Rescue. Cell Metabolism 2014, 19: 209-220. PMID: 24506864, PMCID: PMC3920193, DOI: 10.1016/j.cmet.2013.11.023.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAtherosclerosisCells, CulturedFatty LiverHepatocytesHyperlipidemiasLow Density Lipoprotein Receptor-Related Protein-6Mechanistic Target of Rapamycin Complex 1Mechanistic Target of Rapamycin Complex 2MiceModels, BiologicalMultiprotein ComplexesMutationNon-alcoholic Fatty Liver DiseaseTOR Serine-Threonine KinasesWnt3A ProteinConceptsHepatic de novo lipogenesisFatty liver diseaseElevated plasma LDLTreatment of hyperlipidemiaSp1-dependent activationCholesterol biosynthesisDe novo lipogenesisAtherogenic lipid disordersMolecular genetic basisLiver diseaseFatty liverLDL levelsPlasma lipidsTG levelsLipid disordersPlasma TGPlasma LDLNovo lipogenesisHyperlipidemiaCombined HyperlipidemiaGenetic basisWnt coreceptorNonconservative mutationsAltered expressionPrimary hepatocytes
2011
LRP6 Protein Regulates Low Density Lipoprotein (LDL) Receptor-mediated LDL Uptake*
Ye ZJ, Go GW, Singh R, Liu W, Keramati AR, Mani A. LRP6 Protein Regulates Low Density Lipoprotein (LDL) Receptor-mediated LDL Uptake*. Journal Of Biological Chemistry 2011, 287: 1335-1344. PMID: 22128165, PMCID: PMC3256876, DOI: 10.1074/jbc.m111.295287.Peer-Reviewed Original ResearchConceptsLDL uptakeLDL bindingHigh serum LDL cholesterol levelReceptor-mediated LDL uptakeSerum LDL cholesterol levelsSerum LDL levelsHigh serum LDL levelsLDL cholesterol levelsPeripheral B lymphocytesLDL levelsCholesterol levelsLDL clearanceLRP6 knockdownMutation carriersImpaired functionB lymphocytesLDL receptorLRP6 geneCHO cellsCritical modulatorLDLRLDL endocytosisGreater declineCHO-K1 cellsLRP6
2009
Frequency and Determinants of Lipid Testing in Ischemic Stroke and Transient Ischemic Attack
Smith E, Pan W, Olson D, Reeves M, Ovbiagele B, Peterson E, Fonarow G, Schwamm L. Frequency and Determinants of Lipid Testing in Ischemic Stroke and Transient Ischemic Attack. Stroke 2009, 41: 232-238. PMID: 20035071, DOI: 10.1161/strokeaha.109.567693.Peer-Reviewed Original ResearchConceptsTransient ischemic attackIschemic attackLDL measurementIschemic strokeLipid testingLarger quality improvement programmesLow-density lipoprotein testingTransient ischemic attack admissionsAdditional calendar yearConsecutive ischemic strokeGuidelines-Stroke hospitalsNationwide stroke registryLipid-Lowering TherapyHistory of strokeQuality Improvement ProgramLogistic regression modelsStroke RegistryHospitalized patientsLipoprotein testingAtrial fibrillationLDL levelsClinical managementHospital characteristicsNational guidelinesPatients
2007
Serum lipid profile on admission for ischemic stroke
Smith E, Abdullah A, Amirfarzan H, Schwamm L. Serum lipid profile on admission for ischemic stroke. Neurology 2007, 68: 660-665. PMID: 17325272, DOI: 10.1212/01.wnl.0000255941.03761.dc.Peer-Reviewed Original ResearchConceptsLipid-lowering agentsLow-density lipoproteinStroke/TIALDL goalLDL targetsNational Cholesterol Education Program Adult Treatment Panel guidelinesAdult Treatment Panel guidelinesLow-density lipoprotein levelsIschemic stroke/TIACharacteristics of patientsSerum lipid profileATPIII guidelinesCardiovascular eventsIschemic strokeLipoprotein levelsLDL levelsLipid profileMultivariable modelPanel guidelinesLipid measurementsNational guidelinesTherapeutic targetGreater riskPatientsCalendar time
1997
Lipoprotein Modification by Advanced Glycosylation Endproducts (AGEs): Role in Atherosclerosis
Bucala R. Lipoprotein Modification by Advanced Glycosylation Endproducts (AGEs): Role in Atherosclerosis. Trends In Cardiovascular Medicine 1997, 7: 39-47. PMID: 21235862, DOI: 10.1016/s1050-1738(96)00137-5.Peer-Reviewed Original ResearchLow-density lipoproteinDiabetic patientsLDL levelsElevated LDL levelsEnzyme-linked immunosorbent assay (ELISA) techniqueRecent clinical observationsAdvanced glycosylation reactionsImmunosorbent assay (ELISA) techniqueVascular diseaseVascular pathologyVascular permeabilityNormal controlsClinical observationsAdvanced glycosylationLipoprotein depositionVascular wallClearance mechanismsNitric oxidePatientsRadical generating systemELISA analysisAgeLipoproteinOxidative modification
1996
What is the effect of hyperglycemia on atherogenesis and can it be reversed by aminoguanidine?
Bucala R. What is the effect of hyperglycemia on atherogenesis and can it be reversed by aminoguanidine? Diabetes Research And Clinical Practice 1996, 30: s123-s130. PMID: 8964186, DOI: 10.1016/s0168-8227(96)80048-9.Peer-Reviewed Original ResearchConceptsDiabetic patientsLDL levelsEndothelium-derived relaxing factorsElevated LDL levelsEffects of hyperglycemiaLow-density lipoproteinRelaxing factorsVascular diseaseVascular pathologyVascular permeabilityNormal controlsClinical observationsAdvanced glycosylationLipoprotein depositionVascular wallELISA techniqueClearance mechanismsNitric oxideClearance kineticsPatientsELISA analysisLDLAgeAminoguanidineLipoprotein
1995
Advanced Glycosylation Endproducts in Diabetic Renal Disease: Clinical Measurement, Pathophysiological Significance, and Prospects for Pharmacological Inhibition
Bucala R, Vlassara H. Advanced Glycosylation Endproducts in Diabetic Renal Disease: Clinical Measurement, Pathophysiological Significance, and Prospects for Pharmacological Inhibition. Blood Purification 1995, 13: 160-170. PMID: 7619388, DOI: 10.1159/000170199.Peer-Reviewed Original ResearchConceptsAdvanced glycosylation endproductsDiabetic renal diseaseNormal renal functionInactivate nitric oxideSpecific therapeutic modalitiesTissue LDL receptorsForms of LDLRenal functionRenal diseaseLDL levelsTherapeutic modalitiesVascular permeabilityPathophysiological significanceAdvanced glycosylationLipoprotein depositionPharmacological inhibitionLDL receptorClinical measurementsNitric oxideEndothelial cellsMarked increaseMiddle moleculesLDLToxic effectsEndproducts
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply